Education
About Us
Working with TipRanks
Follow Us
BioVie (BIVI)
NASDAQ:BIVI
BIVI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.62 - $7.50
Previous CloseN/A
Volume1.62M
Average Volume (3M)221.95K
Market Cap
$14.65M
Enterprise Value$1.75M
Total Cash (Recent Filing)$45.75M
Total Debt (Recent Filing)$13.37M
Price to Earnings (P/E)―
Beta2.03
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.95
Shares Outstanding18,451,980
10 Day Avg. Volume194,946
30 Day Avg. Volume221,947
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.62
Enterprise Value/Ebitda-0.08
Forecast
1Y Price Target
$6.00Price Target Upside631.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
BioVie News
PremiumCompany Announcements
BioVie Raises $3.24 Million in Direct Offering---
Ownership Overview
9.37% Insiders
1.15% Mutual Funds
0.22% Other Institutional Investors
86.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BIVI FAQ
What was BioVie’s price range in the past 12 months?
BioVie lowest stock price was $0.62 and its highest was $7.50 in the past 12 months.
What is BioVie’s market cap?
BioVie’s market cap is $14.65M.
When is BioVie’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BioVie’s earnings last quarter?
BioVie released its earnings results on Feb 14, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.055.
Is BioVie overvalued?
According to Wall Street analysts BioVie’s price is currently Undervalued.
Does BioVie pay dividends?
BioVie does not currently pay dividends.
What is BioVie’s EPS estimate?
BioVie’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioVie have?
BioVie has 18,451,980 shares outstanding.
What happened to BioVie’s price movement after its last earnings report?
BioVie reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -0.823%.
Which hedge fund is a major shareholder of BioVie?
Among the largest hedge funds holding BioVie’s share is Sheaff Brock Investment Advisors LLC. It holds BioVie’s shares valued at 0.
---
BioVie Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (631.71% Upside)
$6.00 (631.71% Upside)
Hedge Fund Trend
Decreased
By 5.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.67%
12-Months-Change
Fundamentals
Return on Equity
-154.54%
Trailing 12-Months
Asset Growth
19.56%
Trailing 12-Months
Company Description
BioVie
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
---
BIVI Stock 12 Month Forecast
Average Price Target
$6.00
▲(631.71% Upside)
Technical Analysis
Best Analysts Covering BIVI
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-20.70%
initiated a buy rating last month
Copying Tyler Bussian's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -20.70% per trade.
---